Genpharmasec share price
BSE: 531592Commercial Services & SuppliesSmall Cap
Last close ₹0.99down ₹0.03 (2.94%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹1.02.
52-week range of traded prices to 23 Oct 2026
₹0.75Low, 30 Mar 2026₹1.84High, 27 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹55 Cr3,222nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 May 2026
- 0.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- −1.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 21 May 2026
- 0.50
- Volume, BSEVolume. Shares traded on the last trading day.
- 4,22,891
Results
Standalone, as consolidated accounts are on record for only 3 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 11 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹45 Crdown 13.32%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1.57 Crdown 32.29%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 3.5%
Revenue by year
Peak revenue ₹131 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
| ₹ crore | Sep 2024Filed 12 Nov | Dec 2024Filed 10 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 7 Aug | Sep 2025Filed 6 Nov | Dec 2025Filed 9 Feb | Mar 2026Filed 21 May | Jun 2026Filed 11 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.8 | 8.3 | 13.6 | 12.1 | 31.6 | 36.0 | 51.7 | 44.8 |
| Net profit | 1.0 | 1.1 | −0.2 | 1.6 | 0.8 | 0.8 | 2.3 | 1.6 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 17.3% | 13.5% | −1.7% | 12.9% | 2.6% | 2.1% | 4.5% | 3.5% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- PharmaceuticalsPharmaceuticals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹131 Crup 301.99%93.5%
- Manufacturing & ProcessingManufacturing & Processing, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹8 Cr5.8%
- Laboratory TestingLaboratory Testing, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1 Crdown 13.63%0.7%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 1% of 1,137 trading days over the last 5 years.
LowestHighest
Its median5.8Industry median1.2
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.62.7
At or below today's level on 1% of 574 trading days over the last 3 years.
LowestHighest
Its median246.9Industry median19.6
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −58.7% | +120.7% | −81.3% | 0.0% |
| 3 years | −36.9% | +35.7% | −53.5% | 0.0% |
| 5 years | −37.2% | +16.7% | −46.2% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Trading & Distributors, 196 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Genpharmasec in market cap.
Genpharmasec is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Minal IndustriesMINALIND | 62 | 166.3 | 1.2 | 108.3 | −6.0% | – | 0.7% | 0.0% | 0.00% |
 Bombay Cycle & Motor AgencyBOMBCYC | 61 | 27.8 | 2.1 | 30.0 | +21.6% | – | 7.9% | 5.4% | 0.33% |
 Constronics InfraCONSTRONIC | 57 | 22.8 | 1.4 | 31.5 | – | – | 6.3% | 3.6% | 0.00% |
 Fortune InternationalFORINTL | 57 | 14.5 | 1.2 | – | – | −13.6% | 8.5% | −0.5% | 0.00% |
| Gautam EximGEL | 54 | 240.7 | 4.0 | – | −18.4% | +67.0% | 1.7% | – | 0.00% |
 Ganesha EcoverseGANVERSE | 53 | – | 1.5 | – | −95.0% | – | −13.6% | −14.2% | 0.00% |
 Palred TechnologiesPALREDTEC | 52 | – | 1.2 | – | +7.5% | – | −8.1% | −4.2% | 0.00% |
 Dhanlaxmi CotexDHANCOT | 51 | – | 0.7 | – | +46.1% | – | – | −2.1% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
14 Oct · Intimation Regarding Change Of Name Of Subsidiary Of The Company
Sep 2026
Genpharmasec share price by year
Each calendar year to 2025.Genpharmasec share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1.31 | −57.5% | 3.41 | 1.31 |
| 2024 | 3.08 | −34.0% | 8.71 | 1.93 |
| 2023 | 4.67 | +12.8% | 5.10 | 2.77 |
| 2022 | 4.14 | −21.1% | 10.08 | 3.87 |
| 2021 | 5.25 | −51.4% | 11.26 | 5.24 |
| 2020 | 10.80 | −18.2% | 15.85 | 10.21 |
| 2019 | 13.20 | +1.0% | 17.25 | 9.70 |
| 2018 | 13.07 | +187.3% | 13.07 | 3.52 |
| 2017 | 4.55 | +166.9% | 5.10 | 2.05 |
| 2016 | 1.71 | – | 1.71 | 1.31 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2018 is from its first session, 7 Feb 2018. 2016 is from its first session, 20 Dec 2016. The 2017 close is its last trade, on 17 Nov 2017.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 0.99 | 1.02 | 0.96 | 0.99 | 0.99 | 4,22,891 |
| 22 Oct 2026 | 0.96 | 1.02 | 0.94 | 1.02 | 0.97 | 5,25,755 |
| 21 Oct 2026 | 1.01 | 1.03 | 0.96 | 0.99 | 0.99 | 6,95,510 |
| 19 Oct 2026 | 1.06 | 1.09 | 1.01 | 1.01 | 1.02 | 10,97,244 |
| 16 Oct 2026 | 1.00 | 1.14 | 0.99 | 1.07 | 1.05 | 6,87,960 |
| 15 Oct 2026 | 1.01 | 1.01 | 0.99 | 1.00 | 1.00 | 2,40,640 |
| 14 Oct 2026 | 1.02 | 1.02 | 0.99 | 1.02 | 1.01 | 1,81,459 |
| 13 Oct 2026 | 1.00 | 1.02 | 0.99 | 1.00 | 1.00 | 5,68,110 |
| 12 Oct 2026 | 0.98 | 1.04 | 0.98 | 1.00 | 1.00 | 4,07,123 |
| 9 Oct 2026 | 1.07 | 1.08 | 0.95 | 1.00 | 1.01 | 8,77,079 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 9 Jan 2024 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 9 Jan 2024 | Price move | – | A corporate action went ex within three days of this move (Right Issue of Equity Shares, ex-date 9 Jan 2024), and its terms do not account for the move. Not adjusted for. |
| 11 Apr 2019 | Split | 0.1000 | Each share became 10. |
| 20 Dec 2016 | Price move | – | This is the share's first trade after a corporate action (Reduction of Capital, ex-date 3 Aug 2016), and the action's terms do not account for the move. Earlier prices are not shown. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- Legal name
- GENPHARMASEC LIMITED
- BSE code
- 531592
- ISIN
- INE861N01036
- Industry
- Commercial Services & Supplies
- Listed
- Apr 1996
- Face value
- ₹1
- CIN
- L24231MH1992PLC323914
- Corporate identity number, the registrar of companies' code for it